Compare VSAT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | BMRN |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 11.4B |
| IPO Year | 1996 | 1999 |
| Metric | VSAT | BMRN |
|---|---|---|
| Price | $71.68 | $66.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 18 |
| Target Price | $59.80 | ★ $88.22 |
| AVG Volume (30 Days) | 2.0M | ★ 2.2M |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.42 | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $5.32 | $15.02 |
| Revenue Next Year | $3.57 | $12.23 |
| P/E Ratio | ★ N/A | $85.87 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $26.10 | $49.26 |
| 52 Week High | $93.03 | $70.98 |
| Indicator | VSAT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 55.43 |
| Support Level | $67.49 | $58.03 |
| Resistance Level | $75.57 | $66.28 |
| Average True Range (ATR) | 3.62 | 2.06 |
| MACD | -1.38 | -0.36 |
| Stochastic Oscillator | 11.59 | 43.22 |
Viasat Inc an world-wide provider of communications technologies and services, focused on making connectivity accessible, available and secure for current and future customers world-wide. The company has two reportable segments: communication services and defense and advanced technologies. It generates majority of revenue from communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers. It has presence in United States and Outside United States. The company generates majority of revenue from United States. Its products are Antennas, Terminals & radios, Modems, Semiconductors, Cybersecurity, Software & services, Home internet.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.